ZATTARIN, EMMA

ZATTARIN, EMMA  

Universita' degli Studi di MILANO  

Mostra records
Risultati 1 - 14 di 14 (tempo di esecuzione: 0.0 secondi).
Titolo Data di pubblicazione Autori Tipo File Abstract
Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study 2020 Zattarin, EFabbroni, CLigorio, FCorti, CBernocchi, OSirico, MCurigliano, GDe Braud, FGMVernieri, C + Article (author) -
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) 2022 Mennitto A.Zattarin E.Di Lorenzo G.Sepe P.Ottini A.De Braud F. G.Verzoni E. + Article (author) -
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin 2022 Zattarin, EmmaNichetti, FedericoLigorio, FrancescaMazzeo, LauraLobefaro, RiccardoFuca, GiovanniPeverelli, GiorgiaVingiani, Andreade Braud, FilippoVernieri, Claudio + Article (author) -
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 2022 Zattarin E.Oresti S.Pizzutilo E. G. + Article (author) -
Evaluation of drug-drug interactions in EGFR-mutated non-small-cell lung cancer patients during treatment with tyrosine-kinase inhibitors 2021 Manglaviti S.Beninato T.Zattarin E.De Braud F. + Article (author) -
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications 2020 Zattarin, ELeporati, RLigorio, FLobefaro, RVingiani, APruneri, GVernieri, C Article (author) -
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients 2021 Ligorio F.Zambelli L.Bottiglieri A.Zattarin E.Ottini A.Vingiani A.Pruneri G.de Braud F. + Article (author) -
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology 2022 Manglaviti S.Beninato T.Zattarin E.Lobefaro R.Bottiglieri A.Apollonio G.de Braud F. G. M. + Article (author) -
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy 2022 Boeri M.Lo Russo G.Manglaviti S.Beninato T.Bottiglieri A.Zattarin E.Galli E. G.de Braud F. G. M. + Article (author) -
Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic 2021 Cavalieri SColombo EBottiglieri AMassa GPlatini FOttini AZattarin EResteghini CAlfieri SDi Martino VLicitra L. + Article (author) -
Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)epositive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy 2020 Ligorio, F.Zambelli, L.Bottiglieri, A.Castagnoli, L.Zattarin, E.Vingiani, A.Pruneri, G.de Braud, F.Vernieri, C. + Article (author) -
Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report 2021 Zattarin E.Ligorio F.Nichetti F.de Braud F. + Article (author) -
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer 2021 Ligorio F.Pellegrini I.Vingiani A.Lobefaro R.Zattarin E.Pruneri G.de Braud F. + Article (author) -
The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (Her2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab 2021 Ligorio F.Zattarin E.Lobefaro R.Zambelli L.Leporati R.de Braud F. + Article (author) -